The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
Open accessAbstract
BACKGROUND: -agonists for symptom relief and have poor adherence to maintenance therapy. Another approach might be for patients to receive a fast-acting reliever plus an inhaled glucocorticoid component on an as-needed basis to address symptoms and exacerbation risk. METHODS: We conducted a 52-week, double-blind, multicenter trial involving patients 12 years of age or older who had mild asthma and were eligible for treatment with regular inhaled glucocorticoids. Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed or budesonide maintenance therapy with twice-daily budesonide (200 μg) plus terbutaline (0.5 mg) used as needed. The primary analysis compared budesonide-formoterol used as needed with budesonide maintenance therapy with regard to the annualized rate of severe exacerbations, with a prespecified noninferiority limit of 1.2. Symptoms were assessed according to scores on the Asthma Control Questionnaire-5 (ACQ-5) on a scale from 0 (no impairment) to 6 (maximum impairment). RESULTS: A total of 4215 patients underwent randomization, and 4176 (2089 in the budesonide-formoterol group and 2087 in the budesonide maintenance group) were included in the full analysis set. Budesonide-formoterol used as needed was noninferior to budesonide maintenance therapy for severe exacerbations; the annualized rate of severe exacerbations was 0.11 (95% confidence interval [CI], 0.10 to 0.13) and 0.12 (95% CI, 0.10 to 0.14), respectively (rate ratio, 0.97; upper one-sided 95% confidence limit, 1.16). The median daily metered dose of inhaled glucocorticoid was lower in the budesonide-formoterol group (66 μg) than in the budesonide maintenance group (267 μg). The time to the first exacerbation was similar in the two groups (hazard ratio, 0.96; 95% CI, 0.78 to 1.17). The change in ACQ-5 score showed a difference of 0.11 units (95% CI, 0.07 to 0.15) in favor of budesonide maintenance therapy. CONCLUSIONS: In patients with mild asthma, budesonide-formoterol used as needed was noninferior to twice-daily budesonide with respect to the rate of severe asthma exacerbations during 52 weeks of treatment but was inferior in controlling symptoms. Patients in the budesonide-formoterol group had approximately one quarter of the inhaled glucocorticoid exposure of those in the budesonide maintenance group. (Funded by AstraZeneca; SYGMA 2 ClinicalTrials.gov number, NCT02224157 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma
Suissa, S., Ernst, P., Benayoun, S., Baltzan, M., & Cai, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430504 · Cited by 1,100
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
Pauwels, R. A., Pedersen, S., Busse, W. W., Tan, W. C., Chen, Y.-Z., Ohlsson, S. V., Ullman, A., Lamm, C. J., & O'Byrne, P. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12891-7 · Cited by 763
Self-citationInhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715274 · Cited by 645
Self-citationCompliance, Adherence, and Concordance
Horne, R. (2006) · Chest · doi:10.1378/chest.130.1_suppl.65s · Cited by 602
Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study
Partridge, M. R., van der Molen, T., Myrseth, S.-E., & Busse, W. W. (2006) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-6-13 · Cited by 495
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.
Suissa, S., Ernst, P., Boivin, J. F., Horwitz, R. I., Habbick, B., Cockroft, D., Blais, L., McNutt, M., Buist, A. S., & Spitzer, W. O. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.3.8118625 · Cited by 422
Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma
Papi, A., Canonica, G. W., Maestrelli, P., Paggiaro, P., Olivieri, D., Pozzi, E., Crimi, N., Vignola, A. M., Morelli, P., Nicolini, G., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063861 · Cited by 365
Williams, L. K., Peterson, E. L., Wells, K., Ahmedani, B. K., Kumar, R., Burchard, E. G., Chowdhry, V. K., Favro, D., Lanfear, D. E., & Pladevall, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.09.011 · Cited by 347
Martinez, F. D., Chinchilli, V. M., Morgan, W. J., Boehmer, S. J., Lemanske, R. F., Mauger, D. T., Strunk, R. C., Szefler, S. J., Zeiger, R. S., Bacharier, L. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62145-9 · Cited by 341
Cited by
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715274 · Cited by 645
Self-citationPorsbjerg, C., Melén, E., Lehtimäki, L., & Shaw, D. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02125-0 · Cited by 575
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02730-2021 · Cited by 537
Self-citationGlobal Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Self-citationImproving lung health in low-income and middle-income countries: from challenges to solutions
Meghji, J., Mortimer, K., Agusti, A., Allwood, B. W., Asher, I., Bateman, E. D., Bissell, K., Bolton, C. E., Bush, A., Celli, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00458-x · Cited by 470
Self-citationControlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
Beasley, R., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., Harrison, T., Houghton, C., Oldfield, K., Papi, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901963 · Cited by 466
Self-citationReddel, H. K., FitzGerald, J. M., Bateman, E. D., Bacharier, L. B., Becker, A., Brusselle, G., Buhl, R., Cruz, A. A., Fleming, L., Inoue, H., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01046-2019 · Cited by 390
Self-citationKey recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update
Levy, M. L., Bacharier, L. B., Bateman, E., Boulet, L.-P., Brightling, C., Buhl, R., Brusselle, G., Cruz, A. A., Drazen, J. M., Duijts, L., et al. (2023) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-023-00330-1 · Cited by 361
Self-citationThe Global Initiative for Asthma (GINA): 25 years later
Boulet, L.-P., Reddel, H. K., Bateman, E., Pedersen, S., FitzGerald, J. M., & O'Byrne, P. M. (2019) · European Respiratory Journal · doi:10.1183/13993003.00598-2019 · Cited by 296
Self-citationHardy, J., Baggott, C., Fingleton, J., Reddel, H. K., Hancox, R. J., Harwood, M., Corin, A., Sparks, J., Hall, D., Sabbagh, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31948-8 · Cited by 280
Self-citationvan de Hei, S. J., Poot, C. C., van den Berg, L. N., Meijer, E., van Boven, J. F. M., Flokstra-de Blok, B. M. J., Postma, M. J., Chavannes, N. H., & Kocks, J. W. H. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001400 · Cited by 22
Metadata
- Authors
- Bateman, E. D., Reddel, H. K., O’Byrne, P. M., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Siwek-Posluszna, A., & FitzGerald, J. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-17
- Volume
- 378
- Issue
- 20
- Pages
- 1877-1887
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2804556773
- Cited by
- 516
- References
- 29
- FWCI
- 39.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.